90 completed, 33 unknown, 23 recruiting, 18 active not recruiting. 189 Phase 2, 32 Phase 1, 31 Phase 3.
Follow Prednisolone: new trials by email Literature Review of Prednisolone trials Research Report on Prednisolone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 290 | 2026-12-14 | 2026-11-02 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction Dovramilast, Prednisolone, Thalidomide - Erythema Nodosum Leprosum | Phase 2 | Recruiting | Medicines Development for Global Health | 45 | 2026-10-12 | 2026-11-03 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-10-15 |
| A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) MK-1045, Rituximab, Rituximab biosimilar - Follicular Lymphoma | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-06-22 | 2026-10-26 |
| Colchicine for Autoimmune and Subacute Thyroiditis colchicine, Prednisolone, NSAID - Hashimoto Thyroiditis, Subacute Thyroiditis | Phase 2 / Phase 3 | Recruiting | Mansoura University | 300 | 2026-06-15 | 2026-07-29 |
| Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis Steroid, Antibiotic - Granulomatous Mastitis | Phase 1 / Phase 2 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 72 | 2026-03-15 | 2026-03-06 |
| Comparison of Quality of Life During a Flare of Crohn's Disease Treated With Prednisolone or aCDED With PEN in Adult Patients aCDED + Modulen, Prednisolone - Crohn Disease, Nutrition Assessment | Phase 2 | Recruiting | University Hospital Tuebingen | 52 | 2026-02-01 | 2026-02-05 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 181 | 2026-01-13 | 2026-09-29 |
| Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Recruiting | Vector Y Therapeutics | 36 | 2025-12-19 | 2026-10-30 |
| Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators ASP2957, Methylprednisolone, Prednisolone - X-Linked Myotubular Myopathy | Phase 1 / Phase 2 | Recruiting | Astellas Gene Therapies | 9 | 2025-12-15 | 2026-09-03 |
| Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder Complement protein C5 inhibitor, IVMP - Neuromyelitis Optica Spectrum Disorder Attack | Phase 2 | Withdrawn | Tianjin Medical University General Hospital | 2025-09-03 | 2025-09-10 | |
| A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL TRS005, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang Teruisi Pharmaceutical Inc. | 66 | 2025-09-01 | 2025-08-22 |
| A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer ASP5541, Prednisone, Prednisolone - Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 218 | 2025-08-19 | 2026-09-03 |
| Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) Avacopan, Prednisone, Methylprednisolone (drug) - IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Mayo Clinic | 16 | 2025-06-09 | 2026-10-09 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| A Study to Prevent Infantile Spasms Relapse Prednisolone, Famotidine, Placebo - Infantile Spasms, Infantile Epileptic Spasms Syndrome | Phase 2 | Recruiting | University of California, Los Angeles | 40 | 2025-05-05 | 2025-05-08 |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) Zilovertamab vedotin, Rituximab, Cyclophosphamide - Lymphoma, Large B-Cell, Diffuse | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 594 | 2025-04-11 | 2026-11-03 |
Showing 20 of 189. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (18) · Lymphoma (17) · Prostatic Neoplasms (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Arthritis, Rheumatoid (7) · Asthma (5) · Hodgkin Disease (5) · Leukemia (5) · Lymphoma, Follicular (5) · Lymphoma, Non-Hodgkin (5) · Burkitt Lymphoma (4) · Leukemia, Biphenotypic, Acute (4) · Lymphoma, B-Cell (4) · Neoplasms (4) · Recurrence (4)
AstraZeneca (5) · Janssen Research & Development, LLC (5) · Merck Sharp & Dohme LLC (5) · Novartis Pharmaceuticals (5) · St. Jude Children's Research Hospital (4) · Zalicus (4) · Assiut University (3) · Children's Oncology Group (3) · GlaxoSmithKline (3) · London School of Hygiene and Tropical Medicine (3) · National Cancer Institute (NCI) (3) · Post Graduate Institute of Medical Education and Research, Chandigarh (3) · University College, London (3) · Asan Medical Center (2) · Genentech, Inc. (2)
United States (56) · United Kingdom (42) · Germany (25) · Canada (18) · South Korea (18) · China (17) · France (17) · Italy (13) · Poland (12) · Spain (12) · Japan (11) · Australia (10) · Egypt (10) · Belgium (9) · Netherlands (9)
Margaret Lee, PhD (4) · Fumihiko Hayakawa, MD (2) · Nicholas D. James, MD (2) · Tomoki Naoe, MD (2) · Wei Xu, M.D., Ph.D. (2) · Aiman Obed, PD Dr. (1) · Aliaa A Bedeir, BDS (1) · Allen Eng Juh Yeoh, MBBS (1)
PMID 33270906, PMID 37505794, PMID 38299639, PMID 15315963, PMID 16344315, PMID 17296644, PMID 18035553, PMID 18223280, PMID 18424759, PMID 18557726, PMID 18559976, PMID 18972276, PMID 18990168, PMID 19066739, PMID 19656525, PMID 19846889, PMID 20236866, PMID 20380712, PMID 20548096, PMID 22409880, PMID 22452894, PMID 22747660, PMID 22752636, PMID 22806274, PMID 23529285, PMID 23607606, PMID 23625982, PMID 24105751, PMID 24220559, PMID 24347141, PMID 24403232, PMID 24504810, PMID 24526257, PMID 24787968, PMID 24802773, PMID 25146720, PMID 25320340, PMID 25425730, PMID 26413982, PMID 26504153, PMID 26718929, PMID 26719232, PMID 26812052, PMID 26849853, PMID 26867033, PMID 28300506, PMID 28388956, PMID 28578639, PMID 28945869, PMID 28978139
U10CA180886 (6), 2025 (5), 2023 (4), 2005 (2), 2008 (2), 2016 (2), 2017 (2), 2018 (2), 2019 (2), U01AA021886 (2), 2004 (1), 2009 (1), 2015 (1), K12HD043494 (1), P30CA022453 (1)